周一“星”视角|围手术期特瑞普利单抗联合NAC可能改善可切除食管癌的疗效；特瑞普利单抗联合化疗和放疗治疗初治晚期ESCC

文章预览

本期胸小星将为大家带来 围手术期特瑞普利单抗联合NAC可能改善可切除食管癌的疗效 ； 特瑞普利单抗联合化疗和放疗治疗初治晚期ESCC ，一起来看看吧！ 2017·EATTS  01 Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial Yan Zheng1, GuanghuiLiang1, DongfengYuan1, XianbenLiu1, YufengBa1, Zimin Qin1, SiningShen1, ZhenxuanLi1, HaiboSun1, BaoxingLiu1, Quanli Gao2, PengLi1, ZongfeiWang1, ShileiLiu1, JianpingZhu1, Haoran Wang1, HaiboMa1, ZhenzhenLiu3, FeiZhao3, JunZhang3, HeZhang4, DaoyuanWu4, JinrongQu5, JieMa6, PengZhang7, Wenjie Ma7, MingYan1, YongkuiYu1, QingLi8, JiangongZhang9, WenqunXing1. 1 Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China. 2 Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou Univers ………………………………